IBIO - iBio Inc Stock Price, Fair Value and News

1.78USD-0.11 (-5.82%)Market Closed

Market Summary

USD1.78-0.11

Market Closed

-5.82%

IBIO Stock Price

View Fullscreen

IBIO RSI Chart

IBIO Valuation

Market Cap

6.2M

Price/Earnings (Trailing)

-0.23

Price/Sales (Trailing)

2.14

Price/Free Cashflow

-0.33

IBIO Price/Sales (Trailing)

IBIO Profitability

Return on Equity

-296.66%

Return on Assets

-80.2%

Free Cashflow Yield

-304.55%

IBIO Fundamentals

IBIO Revenue

Revenue (TTM)

2.1M

IBIO Earnings

Earnings (TTM)

-27.3M

Earnings Growth (Yr)

75.53%

Earnings Growth (Qtr)

-42.9%

Breaking Down IBIO Revenue

Last 7 days

-6.9%

Last 30 days

79.1%

Last 90 days

74.1%

Trailing 12 Months

74.1%

How does IBIO drawdown profile look like?

IBIO Financial Health

Current Ratio

0.91

IBIO Investor Care

Shares Dilution (1Y)

463.38%

Diluted EPS (TTM)

-10.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	2.5M	2.1M	0	0
2021	3.0M	2.4M	2.0M	1.5M
2020	1.3M	1.6M	1.9M	2.3M
2019	1.3M	2.0M	2.1M	1.7M
2018	500.0K	444.0K	367.0K	865.0K
2017	522.0K	394.0K	381.0K	459.0K
2016	989.0K	948.0K	923.0K	864.0K
2015	1.4M	1.9M	1.2M	959.0K
2014	0	205.0K	616.5K	1.0M
2013	741.1K	1.0M	0	0
2012	1.1M	1.3M	1.3M	1.1M
2011	0	520.1K	709.3K	898.5K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of iBio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 01, 2023	brenner martin	sold	-1,295	0.2655	-4,881	see remarks
Oct 03, 2023	brenner martin	sold	-1,591	0.3022	-5,267	see remarks
Oct 02, 2023	brenner martin	sold	-1,310	0.311	-4,215	see remarks
Aug 28, 2023	brenner martin	sold	-1,528	0.3051	-5,011	see remarks
Jul 27, 2023	brenner martin	sold	-2,307	0.511091	-4,515	see remarks
Jul 12, 2023	brenner martin	sold	-27,520	0.5853	-47,020	see remarks
Jun 26, 2023	brenner martin	acquired	-	-	75,833	see remarks
Jun 22, 2023	brenner martin	back to issuer	-	-	-75,833	see remarks
Jun 21, 2023	brenner martin	sold	-2,848	0.680898	-4,184	see remarks
May 22, 2023	brenner martin	sold	-3,910	0.935057	-4,182	see remarks

Which funds bought or sold IBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 11, 2024	CITY HOLDING CO	unchanged	-	11.00	16.00	-%
Apr 10, 2024	SOA Wealth Advisors, LLC.	unchanged	-	35.00	53.00	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-76,166	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-10,000	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	sold off	-100	-243	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	new	-	55.00	55.00	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	34,780	34,780	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	new	-	69.00	69.00	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%

Are Funds Buying or Selling IBIO?

Are funds buying IBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IBIO

No. of Funds

Unveiling iBio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	opaleye management inc.	7.63%	650,000	SC 13G/A
Apr 08, 2024	opaleye management inc.	7.63%	650,000	SC 13G
Apr 05, 2024	adar1 partners, lp	9.27%	789,293	SC 13G
Apr 01, 2024	lynx1 capital management lp	9.99%	878,492	SC 13G
Feb 13, 2024	vanguard group inc	0.23%	8,439	SC 13G/A
Jan 04, 2024	sabby management, llc	9.99%	200,303	SC 13G
Feb 09, 2023	vanguard group inc	5.28%	475,593	SC 13G
Jul 08, 2022	blackrock inc.	1.8%	3,960,718	SC 13G
Feb 03, 2022	blackrock inc.	7.1%	15,476,683	SC 13G/A
Feb 02, 2021	blackrock inc.	5.5%	11,575,051	SC 13G

Recent SEC filings of iBio Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	S-3	S-3
Apr 09, 2024	SC 13G/A	Major Ownership Report
Apr 08, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 04, 2024	D	D
Apr 01, 2024	SC 13G	Major Ownership Report
Apr 01, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Feb 21, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to iBio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-0.79%	-27.48%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	7.98%	-8.04%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-8.07%	-28.58%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-0.50%	-10.21%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-10.79%	209.42%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	3.17%	4.73%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	79.05%	74.07%	-0.23	2.14	-13.45%	66.37%

iBio Inc News

Latest updates

iBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-	-	-	-	1,800	168	84.00	491	765	705	410	1,120	96.00	314	108	795	527	651	45.00	91.00	78.00	153
Gross Profit	-	-	-	46.00	1,895	55.00	171	72.00	272	494	303	-	10.00	-	-	-	-	-	-	-	-	-
Operating Expenses	-12.7%	4,496	5,153	10,453	8,588	7,231	5,309	9,511	7,475	8,039	7,227	3,591	4,074	3,469	3,963	4,848	4,297	4,666	3,995	4,037	3,571	-
S&GA Expenses	-16.5%	2,961	3,547	6,891	5,316	5,372	4,175	6,167	5,313	5,665	5,365	2,993	2,979	2,581	2,986	3,224	2,844	3,393	2,871	2,995	2,605	-
R&D Expenses	-4.4%	1,535	1,606	3,562	3,272	1,859	1,134	3,344	2,162	2,374	1,862	598	1,095	888	977	1,624	1,453	1,273	1,124	1,042	966	-
Interest Expenses	30.8%	34.00	26.00	310	-	-	610	613	612	615	614	615	616	615	620	474	474	476	476	478	478	-
Net Income	-42.9%	-8,211	-5,746	-17,054	-12,390	-11,920	-8,940	118	-7,661	-8,131	-7,534	-3,536	-4,676	-3,764	-4,464	-4,502	-4,223	-4,470	-4,399	-8,244	-3,962	-
Net Income Margin	0%	-25.65*	-25.65*	-24.51*	-13.03*	-18.84*	-12.04*	-9.79*	-8.95*	-10.24*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	11.9%	-4,706	-5,340	-14,933	-6,588	-12,819	-10,470	-9,740	-8,342	-9,413	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.7%	34.00	38.00	41.00	44.00	52.00	85.00	99.00	115	126	144	147	143	145	117	94.00	42.00	36.00	35.00	31.00	36.00	40.00
Current Assets	-14.4%	20.00	23.00	26.00	27.00	38.00	64.00	45.00	60.00	67.00	90.00	105	107	111	85.00	62.00	10.00	4.00	2.00	5.00	10.00	14.00
Cash Equivalents	90.8%	3.00	1.00	4.00	7.00	4.00	16.00	29.00	40.00	45.00	63.00	77.00	85.00	91.00	78.00	55.00	10.00	4.00	2.00	4.00	9.00	13.00
Inventory	-	-	-	-	-	-	-	4.00	3.00	2.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.0%	4.00	4.00	4.00	4.00	4.00	3.00	1.00	35.00	33.00	10.00	9.00	6.00	5.00	4.00	4.00	3.00	3.00	3.00	24.00	25.00	25.00
Liabilities	1.5%	25.00	24.00	26.00	27.00	33.00	36.00	36.00	36.00	36.00	43.00	38.00	38.00	38.00	37.00	38.00	38.00	37.00	37.00	28.00	29.00	29.00
Current Liabilities	4.1%	22.00	21.00	22.00	22.00	28.00	32.00	30.00	8.00	8.00	8.00	7.00	6.00	6.00	5.00	5.00	6.00	5.00	5.00	3.00	4.00	4.00
Shareholder's Equity	-30.4%	9.00	13.00	15.00	17.00	19.00	48.00	63.00	79.00	91.00	101	109	105	107	80.00	57.00	4.00	-	-	2.00	7.00	11.00
Retained Earnings	-2.8%	-302	-294	-288	-282	-275	-242	-223	-206	-194	-182	-173	-173	-166	-157	-150	-146	-135	-110	-105	-101	-97.09
Additional Paid-In Capital	1.4%	312	308	304	300	295	291	288	286	285	283	282	278	273	238	207	151	135	108	108	108	108
Shares Outstanding	134.6%	3.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-0.02	-0.02	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	0.00	0.00
Float	-	-	-	-	-	5.00	-	-	-	120	-	-	-	222	-	-	-	14.00	-	-	-	7.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	11.9%	-4,706	-5,340	-4,970	-3,872	-7,635	-13,959	-11,503	-5,944	-10,686	-9,347	-7,226	-7,349	-8,419	-7,070	-3,867	-3,786	-3,405	-2,287	-4,392	-4,135	-4,670
Share Based Compensation	-40.4%	456	765	446	1,596	1,127	1,222	1,179	1,274	1,103	821	596	374	265	351	220	63.00	37.00	68.00	59.00	49.00	60.00
Cashflow From Investing	-100.0%	-	50.00	-6.00	8,241	-1,255	29.00	477	517	-972	-5,149	-2,908	-4,014	-12,956	-6,600	-820	-96.00	-208	-30.00	-173	-139	-389
Cashflow From Financing	62.0%	4,005	2,472	2,740	1,464	-3,044	1,141	-10.00	-10.00	-6,017	-88.00	2,912	4,738	35,084	36,101	49,759	10,287	5,146	-	-50.00	-50.00	2,410

IBIO Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss
Revenues			$ 50
Operating expenses:
Research and development	$ 1,535	$ 2,779	3,141	$ 5,327
General and administrative	2,961	7,794	6,508	12,882
Total operating expenses	4,496	10,573	9,649	18,209
Operating loss	(4,496)	(10,573)	(9,599)	(18,209)
Other income (expense):
Interest expense	(34)	(31)	(60)	(31)
Interest income	42	41	97	140
Total other income	8	10	37	109
Net loss attributable to iBio, Inc. from continuing operations	(4,488)	(10,563)	(9,562)	(18,100)
Net loss from continuing operations	(4,488)	(10,563)	(9,562)	(18,100)
Loss from discontinued operations	(3,723)	(22,990)	(4,395)	(33,583)
Net loss	(8,211)	(33,553)	(13,957)	(51,683)
Comprehensive loss:
Consolidated net loss	(8,211)	(33,553)	(13,957)	(51,683)
Other comprehensive loss - unrealized loss on debt securities		56		46
Comprehensive loss	$ (8,211)	$ (33,497)	$ (13,957)	$ (51,637)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations	$ (2.42)	$ (21.54)	$ (6.27)	$ (38.82)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations	(2.42)	(21.54)	(6.27)	(38.82)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations	(2.00)	(46.89)	(2.88)	(72.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations	(2.00)	(46.89)	(2.88)	(72.03)
Loss per common share attributable to iBio, Inc. stockholders - basic - total	(4.42)	(68.43)	(9.15)	(110.85)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total	$ (4.42)	$ (68.43)	$ (9.15)	$ (110.85)
Weighted-average common shares outstanding - basic	1,856	490	1,525	466
Weighted-average common shares outstanding - diluted	1,856	490	1,525	466

IBIO Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,788,000	$ 4,301,000
Restricted cash	1,057,000	3,025,000
Subscription receivable		204,000
Prepaid expenses and other current assets	894,000	664,000
Current assets held for sale	14,960,000	18,065,000
Total Current Assets	19,699,000	26,259,000
Restricted cash	215,000	253,000
Promissory note receivable and accrued interest	1,750,000	1,706,000
Net finance lease ROU assets	475,000	610,000
Operating lease right-of-use asset	2,565,000	2,722,000
Fixed assets, net of accumulated depreciation	3,890,000	4,219,000
Intangible assets, net of accumulated amortization	5,378,000	5,388,000
Security deposits	50,000	50,000
Total Assets	34,022,000	41,207,000
Current liabilities:
Accounts payable	1,859,000	1,849,000
Accrued expenses	3,757,000	4,034,000
Finance lease obligations - current portion	285,000	272,000
Operating lease obligation - current portion	412,000	389,000
Equipment financing payable - current portion	168,000	160,000
Insurance premium financing payable	481,000
Term note payable - net of deferred financing costs	12,655,000	12,937,000
Current liabilities related to assets held for sale	1,936,000	1,941,000
Total Current Liabilities	21,553,000	21,582,000
Finance lease obligations - net of current portion	205,000	351,000
Operating lease obligation - net of current portion	2,912,000	3,125,000
Equipment financing payable - net of current portion	155,000	241,000
Accrued expenses - noncurrent		527,000
Total Liabilities	24,825,000	25,826,000
Stockholders' Equity
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at December 31, 2023 and June 30, 2023; 0 and 0 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively
Common Stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2023 and June 30, 2023; 3,243,725 and 1,015,505 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively	30,000	20,000
Additional paid-in capital	312,064,000	304,301,000
Accumulated deficit	(302,897,000)	(288,940,000)
Total Stockholders' Equity	9,197,000	15,381,000
Total Liabilities and Stockholders' Equity	$ 34,022,000	$ 41,207,000

About iBio Inc

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

CEO	Dr. Martin B. Brenner D.V.M., Ph.D.
WEBSITE	ibioinc.com
INDUSTRY	Biotechnology
EMPLOYEES	105

iBio Inc Frequently Asked Questions

What is the ticker symbol for iBio Inc? What does IBIO stand for in stocks?

IBIO is the stock ticker symbol of iBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iBio Inc (IBIO)?

As of Wed Apr 17 2024, market cap of iBio Inc is 6.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IBIO stock?

You can check IBIO's fair value in chart for subscribers.

What is the fair value of IBIO stock?

You can check IBIO's fair value in chart for subscribers. The fair value of iBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iBio Inc a good stock to buy?

The fair value guage provides a quick view whether IBIO is over valued or under valued. Whether iBio Inc is cheap or expensive depends on the assumptions which impact iBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBIO.

What is iBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, IBIO's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 2.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on iBio Inc's stock?

In the past 10 years, iBio Inc has provided -0.338 (multiply by 100 for percentage) rate of return.